Berger Paints. Result Update. Downgrade to Reduce (Prev. - Accumulate) Valuation (x) Estimates (` mn) Q2FY18 Result (` Mn) November 06, 2017

Similar documents
MRF. Result Update. Accumulate

Bharat Petroleum Corporation

Techno Electric & Engineering

Music Broadcast. Result Update. Buy. Valuation (x) Estimates (` Mn) Q1FY18 Result (` Mn)

HCC. Result Update. Accumulate. Debt reduction factored in. Valuation (x) Estimates (` mn) Q2FY18 Result (` Mn) November 03, 2017

Skipper. Result Update. Reduce

Result Update. Sterling Tools. Buy

NCC. Result Update. Accumulate

Voltas. Result Update. Buy. Q4FY18 Result (` Mn) May 21, 2018

MRF. Result Update. Accumulate

Simplex Infrastructures

Transport Corporation of India

Maruti Suzuki India. Result Update. Accumulate. Growth Story Continues. Valuation (x) Estimates (` mn) Q3FY18 Result (` Mn)

Gujarat State Petronet

Result Update. Ahluwalia Contracts. Buy

Result Update. Atul Auto. Accumulate

GSK Pharma. Result Update. Buy

INOX Leisure. Result Update. Accumulate. Valuation (x) Estimates (` Mn) Q4FY18 Result (` Mn) May 08, 2018

Larsen & Toubro. Result Update. Accumulate. Valuation (x) Estimates (` Bn) Q1FY18 Result (` Mn) July 26, 2018

Result Update. Sterling Tools. Accumulate

Shemaroo Entertainment

Maruti Suzuki India. Result Update. Accumulate. Product mix driving margins

Skipper. Accumulate. Result Update. India (Capital Goods) Institutional Research DOLAT CAPITAL

Skipper. Buy. Result Update. India (Capital Goods) Institutional Research DOLAT CAPITAL

Transport Corporation of India

Result Update. Havells. Buy

Result Update. Khadim India. Buy

Container Corporation of India

Balkrishna Industries

Dilip Buildcon. Result Update. Buy. Stellar performance continues

Result Update. Skipper. Sell

Result Update. Tech Mahindra. Buy

Page Industries. Annual Report Analysis. Accumulate. FINANCIALS (` Mn) July 14, 2017

CONCOR. Management Meeting Update. Buy

Kajaria Ceramics. Result Update. Buy

Infosys. Result Update. Buy

Result Update ITC. Accumulate

Music Broadcast. Annual Report Analysis. Buy. Financials (` mn) August 31, 2018

Result Update. KEI Industries. Buy

Dixon Technologies. Annual Report Analysis. Accumulate. Annual Report The IPO year. FINANCIALS (` Mn)

Result Update. NIIT Technologies. Buy

Mahanagar Gas. Result Update. Accumulate

Particulars Q3FY15 Q3FY14 YoY (%) Q2FY15 QoQ (%) 9MFY15 9MFY14 YoY (%) Net Sales 3,774 3, , ,453 8,

ICICI Bank. Result Update. Buy. Mixed bag. Valuation (x) Estimates (` mn) Q3FY18 Result (` Mn)

Kalpataru Power Transmission

Q3FY19 Quarterly Preview IT Services

Sagar Cement. Result Update. Buy. Valuation (x) Estimates (` mn) Q1FY19 Result (` Mn)

Result Update. HDFC Bank. Accumulate

Dilip Buildcon. Visit Note. Buy. FY18E a bumper year! Show continues!

JK Cement. Result Update. Buy. Q3FY18 Result (` Mn)

ICICI Bank. Result Update. Buy

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Repco Home Finance REPCO IN

KEC International. Annual Report Analysis. Accumulate

Q3FY13 Q3FY12 YOY(%) Q2FY13

Visaka Industries Ltd

Near-term pressure, but long-term outlook positive

Result Update. Yes Bank. Buy

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

Hindustan Unilever (RHS)

Fineotex Chemical Ltd

Cummins India Ltd Bloomberg Code: KKC IN

Asian Paints. Source: Company Data; PL Research

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

Still on track. Exhibit 1: ICT is on track for FY09E

Bayer Cropscience (BYRCS IN)

CMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

Transport Corporation of India Ltd.

Bloomberg Code: ATA IN

Amber Enterprises India Ltd

Mahindra & Mahindra Ltd.

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

TVS Motors. Source: Company Data; PL Research

South Indian Bank. Result Update. Buy

TTK Prestige Ltd. Result Highlights. Revenue growth of 41% YoY, shows no slowdown yet. OPM at ~15.8%; in line with our estimate

Transport Corporation of India Ltd.

SQS India BFSI Ltd HOLD. Impact of Macro Headwinds Still Hurting; Revenue from US May Pick up in FY18E

ITC Ltd. RESULT UPDATE 27th October, 2017

Asian Paints. Source: Company Data; PL Research

Simplex Infrastructures

Mahindra & Mahindra Ltd.

HOLD. Margins to improve from Q2 AMBUJA CEMENTS. Target Price: Rs 232. Other highlights

Mahindra & Mahindra. Source: Company Data; PL Research

MCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

BUY. At inflection point NTPC. Target Price: Rs 197. Key highlights. Financial summary (Standalone) Y/E March FY16 FY17 FY18E FY19E.

Ahluwalia Contracts (India)

Maruti Suzuki (RHS) BUY. Operationally In Line; Reiterate Buy. Automobiles October 31, 2014 RESULT REVIEW. Outlook & Valuation.

Mphasis. Increased confidence on margins. Source: Company Data; PL Research

Sanofi India. Company Update. Buy

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Suzlon Energy Ltd RESULT UPDATE 16th August, 2017

Swaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE

Bata India BUY. Performance Update. CMP Target Price `842. 1QFY2019 Result Update Footwear. Historical share price chart.

Symphony Ltd. RESULT UPDATE 31st October 2017

HOLD. Performance remains weak COLGATE-PALMOLIVE INDIA. Target Price: Rs 900

BLS International Services

Healty cigarette-driven growth

Transcription:

Result Update Berger Paints Downgrade to Reduce (Prev. - Accumulate) Continues to gain market share Revenues (consol.) grew by 11.% YoY to ` 12.bn in-line with our estimate. Standalone revenues were up 11.3% at ` 11.4bn (implied volume growth of ~9%) and subsidiary business witnessed 1.% YoY surge in revenues. The primary analysis suggests that the volume growth was lower compared to APL (~9-1%) and Nerolac (~1%). Gross margins (consol.) contracted by 1bps YoY at 42.9%, due to rise in key RM prices. EBITDA grew by 11.4% YoY at ` 2.bn, while EBITDA margins remained flat YoY to 1.%. Despite contraction in GM and bps increase in employee spends, 17bps decrease in other expenses offset the decline in EBITDA margin. APAT jumped 17.7% YoY to ` 1.1bn. Including OCI and exceptional gain of ` 442mn related to slump sales in Q2FY17, the RPAT jumped 4.1% to ` 1.4bn Berger is gaining -1bps market share annually in past 4- years. After continuously outpacing APL volume growth in past few quarters, for the first time Berger reported lower volume growth. We attribute this to supply hurdles during Jul 17 due to GST implementation. However, new and innovative launches would help the company to gain market share. We believe that the company has lower penetration compared to the leader which presents higher scope for further growth. With better monsoon in the last couple of years, painting activities are expected to increase in coming years. We expect pent-up demand in the system as FY17 was partially impacted by demonetisation and feel good factor remains with better economic conditions, especially in rural markets. Berger, the second largest player in the domestic decorative paint industry is likely to benefit more due to (1) rising distribution reach (2) strong presence in urban markets and (3) attractive product offering in all categories. Further, the company s continuous efforts to improve operating efficiency will enhance operating margins. We expect Berger to report EBITDA margin improvement with stable demand and favorable business conditions Valuing Berger at 43x FY19E EPS to arrive at a TP of ` 263. Downgrade to Reduce. (Prev.- Accumulate). Q2FY1 Result (` Mn) Particulars Q2FY1 Q2FY17 YoY (%) Q1FY1 QoQ (%) Net Revenue 12,17 11,466 11. 12,471 2. Total Expenditure 1,26 9,67 11.9 1,62 1.9 PBIDT (Excl OI) 1,991 1,7 11.4 1,1 7.6 Other Income 11 14 (44.9) 13 (2.) Depreciation 36 273 12.2 3. Interest 76 1.4 2 172. PBT 1,711 1,64 3. 1,64 3.4 Tax 622 73 (14.7) 6 11.9 Profit After Tax 1, 919 1. 1,9 (.9) Minority Interest (2) (27) NM (31) NM APAT 1,113 946 17.7 1,129 (1.4) RPAT 1,421 1,366 4.1 1,32 37.7 bps bps Gross Profit (%) 42.9 43.9 (1) 4.6 23 Employee Exp (%) 7.4 6.6 6.7 7 Other Exp (%) 2. 21.7 (17) 19. 1 EBITDA (%) 1. 1.6 (1) 14. 7 EBIT (%) 13.9 14. (9) 13. PAT (%) 11.1.1 3.3 2 November 6, 217 CMP ` 26 Target / Upside ` 263/3% BSE Sensex 33,731 NSE Nifty 1,41 Scrip Details Equity / FV Market Cap ` 971/`1/- ` 249bn USD 3.bn 2-week High/Low ` 266 / 17 Avg. Volume (no) 7,942 NSE Symbol Bloomberg Code BERGEPAINT Shareholding Pattern Sept 17 (%) BRGR IN Promoters 7. MF/Banks/FIs 3.3 FIIs 11.1 Public / Others 1.6 Valuation (x) FY17 FY1E FY19E P/E 64. 2.9 41.1 EV/EBITDA 34.4 3. 24.4 ROE 24. 23. 2. ROCE 3.4 2. 32.3 Estimates (` mn) FY17 FY1E FY19E Net Sales 4,23,999,74 EBITDA 7,16 7,7 9,779 PAT 4,29 4,697 6,46 EPS 4. 4. 6.2 Sr. Analyst: Sachin Bobade Tel: +9122 496 9731 E-mail: sachinb@dolatcapital.com Associate: Nikhat Koor Tel: +9122 496 9764 E-mail: nikhatk@dolatcapital.com

Apr-1 Oct-1 Apr-11 Oct-11 Apr-12 Oct-12 Apr-13 Oct-13 Apr-14 Oct-14 Apr-1 Oct-1 Mar-16 Sep-16 Mar-17 Jan-13 May-13 Aug-13 Nov-13 Mar-14 Jun-14 Sep-14 Dec-14 Apr-1 Jul-1 Oct-1 Jan-16 May-16 Aug-16 Nov-16 Feb-17 Jun-17 () (3) () (1) 7 11 12 12 14 2 1 1 Revenue growth (%) EBITDA margin (%) 17.4 17 1. 1. 13.3 13.3 13.2 14.1 1.61.614. 14. 1 13 11.4 11.6 11 9 () 7 4 Gross margin (%) Volume Growth (%) 1 4 42 39 41.2 41.9 43. 39.1 43.3 4.4 43. 44.4 43.9 42.2 41. 4.6 42.9 1 () 1.7 6.3 6.3 12.2. 9..9 1.6 2.9.4 6.4 7.2 2.3 4. 4.3 2.2 (2.1)(2.1)(2.6) (4.3) (2.6)(2.6)(2.6) (2.6) 2.7 2.1 36 Price growth Volume growth Trend in Titanium Dioxide Price (INR/KG) Trend in Brent Price (USD) 2 14 2 12 1 1 1 6 4 2 November 6, 217 2

Income Statement (` mn) Net Sales 42,231 4,23,999,74 Other income 347 4 2 64 Total Income 42,7 46,6 1,24 9,396 Total Expenditure 3,74 3,337 43,112 4,97 Cost of RM Consumed 24,72 2,923 29,721 33,2 Employee Expenses 2,73 3,67 3,72 3,96 Selling & Adm.Expenses 2,7 2,413 2,2 2,992 Other Expenses 6,269 6,933 7,317,7 EBIDTA (Excl. OI) 6,447 7,16 7,7 9,779 EBIDTA (Incl. OI) 6,794 7,731,412 1,426 Interest 273 162 2 1 EBDT 6,21 7,69,212 1,239 Depreciation 97 1,1 1,23 1,346 PBT & EO Items,3 6,4 6,96,93 Extra Ordinary Exps/(Inc.) 442 Profit Before Tax,3 6,46 6,96,93 Tax 1,6 2,294 2,377 2,967 Net Profit 3,649 3,72 4,2,926 Share of associates (7) (11) (11) (12) Net Profit (After minority) 3,76 3,3 4,697 6,46 Net Profit (Adj.) 3,76 4,29 4,697 6,46 Balance Sheet (` mn) Sources of Funds Equity Capital 694 971 971 971 Reserves 14,927 1,4 2,9 24,3 Net Worth 1,621 19,16 21,61 2,24 Minority Interest (11) (23) Secured Loans 2,1 2,621 1,4 1,46 Unsecured Loans 1,437 1,441 2,317 2,197 Loan Funds 3,44 4,62 3,62 3,662 Deferred Tax Liability 67 7 7 7 Total Capital Employed 19,43 23, 26,41 29,7 Applications of Funds Gross Block 1,44 13,13 13,3 14,63 Less: Accumulated Dep. 4 1,744 2,996 4,342 Net Block 9,629 11,36 1,7 1,261 Capital Work in Progress 11 622 63 63 Investments 3,47 4,721 4,721 4,721 Current Assets, Loans & Advances Inventories 7,332 9,3 9,6 1,124 Sundry Debtors,44,71 6,224 7,9 Cash and Bank Balance 1,3 1,2 4,947,732 Loans and Advances 1,27 1,3 1,3 1,3 Other Current Assets 47 79 19 19 sub total 1,93 17,624 21,732 27,43 Less: Current Liabilities & Provisions Current Liabilities,67 1,6 1,72 12,339 Provisions 29 36 36 36 sub total,6 1,443 1,9 12,72 Net Current Assets 6,22 7,12 1,774 14,713 Total Assets 19,43 23, 26,41 29,7 E Estimates Cash Flow (` mn) Profit before tax,92 7,31 6,96,93 Depreciation & w.o. 97 1,1 1,23 1,346 Net Interest Exp 273 162 2 1 Direct taxes paid (1,6) (2,294) (2,377) (2,967) Change in Working Capital 1,13 (1,27) 33 (14) Non-Cash (362) (97) (A) CF from Opt. Activities,742 4,17 6,364 7,36 Capex (1,176) (2,644) (191) (7) Free Cash Flow 4,66 1,463 6,173 6,6 (Inc). / Dec. in Investments (1,34) (946) (B) CF from Invt. Activities (2,79) (3,9) (191) (7) Issue of Equity/ Preference 27 Inc./(Dec.) in Debt (2,319) 7 (2) (2) Interest exp net (273) (162) (2) (1) Dividend Paid (Incl. Tax) (1,) (1,169) (1,2) (2,33) (C) CF from Financing (3,677) (46) (2,21) (2,771) Net Change in Cash (644) (29) 3,922 3,7 Opening Cash balances 1,69 1,3 1,2 4,947 Closing Cash balances 1,3 1,2 4,947,732 Important Ratios (A) Measures of Performance (%) EBIDTA Margin (excl. O.I.) 1.3 1. 1. 16.6 EBIDTA Margin (incl. O.I.) 16.1 17. 16. 17.7 EBDT Margin 1.4 16.6 16.1 17.4 Tax/PBT 34.1 37.9 34.2 33.4 Net Profit Margin.6.2 9. 1.1 (B) As Percentage of Net Sales Raw Material. 6.9.3 6.6 Employee Expenses 6. 6.7 7. 6.7 Selling & Adm. Expenses 4.9.3 4.9.1 Other Expenses 14. 1.2 14.3 14.9 (C) Measures of Financial Status Debt / Equity (x).2.2.2.1 Interest Coverage (x) 24.9 47.7 42.2.6 Debtors Period (days) 47.1 46.4 44. 44. Closing stock (days) 63.4 7. 64.9 62.9 Inventory Turnover Ratio (x). 4.9.6. Fixed Assets Turnover (x) 4. 3. 3.7 4. WC Turnover (x) 6. 6.3 4.7 4. Non-Cash WC (` Mn),17 6,17,27,91 (D) Measures of Investment EPS (`) (Reported).3 3.9 4.7 6.1 EPS (`).3 4. 4. 6.2 CEPS (`) 6.. 6.1 7.6 DPS (`) 1.2 1.6 1.6 2. Dividend Payout (%) 23.4 4.3 32.7 32.7 Book Value (`) 22. 19.6 22. 26.3 RoANW (%) 26.3 24. 23. 2. RoACE (%) 29.7 3.4 2. 32.3 RoAIC (%) 31.9 31.9 32.3 42.7 (E) Valuation Ratios CMP (`) 26 26 26 26 P/E (x) 47.9 64. 2.9 41.1 Market Cap. (` Mn) 177,36 24,76 24,76 24,76 MCap/ Sales (x) 4.2. 4.9 4.2 EV (` Mn) 176,1 246,92 242,77 23,7 EV/Sales (x) 4.2.4 4. 4.1 EV/EBDITA (x) 27.4 34.4 3. 24.4 P/BV (x) 11.4 13.1 11.4 9.7 Dividend Yield (%)..6.6. E Estimates November 6, 217 3

Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Oct-17 Nov-17 DART RATING MATRIX Total Return Expectation (12 Months) Buy > 2% Accumulate 1 to 2% Reduce to 1% Sell < % Rating and Target Price History 3 3 2 2 Month Rating TP (`) Price (`)* Aug-16 Reduce 232 242 Nov-16 Reduce 24 29 Oct-17 Accumulate 27 23 * As on Recommendation Date 1 Berger Paints Target DART Team Purvag Shah Managing Director purvag@dolatcapital.com +9122 496 9747 Amit Khurana, CFA Head of Equities amit@dolatcapital.com +9122 496 974 CONTACT DETAILS Equity Sales Designation E-mail Direct Lines Kishor Bagri, CFA VP - Equity Sales kishorb@dolatcapital.com +9122 496 9746 Kartik Sadagopan VP - Equity Sales kartiks@dolatcapital.com +9122 496 9762 Kapil Yadav VP - Equity Sales kapil@dolatcapital.com +9122 496 973 Yomika Agarwal VP - FII Sales yomika@dolatcapital.com +9122 496 9773 Derivatives Strategist Designation E-mail Bhavin Mehta VP - Derivatives Strategist bhavinm@dolatcapital.com +9122 496 97 Equity Trading Designation E-mail P. Sridhar VP and Head of Sales Trading sridhar@dolatcapital.com +9122 496 972 Chandrakant Ware AVP - Equity Sales Trading chandrakant@dolatcapital.com +9122 496 977 Derivatives Trading Designation E-mail Shirish Thakkar AVP - Derivatives shirisht@dolatcapital.com +9122 496 972 Hardik Mehta Sales Trader hardikm@dolatcapital.com +9122 496 974 Dolat Capital Market Private Limited. 2, Rajabahadur Mansion, 1st Floor, Ambalal Doshi Marg, Fort, Mumbai - 4 1

Analyst(s) Certification The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report. I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil) II. Disclaimer: This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions. For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 1a- 6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 1a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity. In reliance on the exemption from registration provided by Rule 1a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered broker-dealer Ltd Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer/entity as informed by Dolat Capital Market Private Limited. from time to time. Dolat Capital Market Private Limited. Corporate Identity Number: U699MH1993PTC719 Member: BSE Limited and National Stock Exchange of India Limited. SEBI Registration No: BSE - INB1712 & INF1712, NSE - INB237131& INF237131, Research: INH6 Registered office: Office No. 141, Centre Point, Somnath, Daman 396 21, Daman & Diu Board: +9122 49697 Fax: +9122 226127 Email: research@dolatcapital.com www.dolatcapital.com Our Research reports are also available on Reuters, Thomson Publishers, DowJones and Bloomberg (DCML <GO>)